Abstracts tagged "atherosclerosis and psoriatic arthritis"

Abstract Number: 2545 • 2017 ACR/ARHP Annual Meeting
Can Achieving Sustained Minimal Disease Activity (MDA) Prevent Progression of Subclinical Atherosclerosis? a Two-Year Prospective Cohort Study in Psoriatic Arthritis
Lydia Ho Pui Tam¹, Tsz Ho CHENG¹, Qing SHANG², Edmund Li³, Priscilla WONG³, Tracy Y. ZHU⁴, M Mimi CHANG⁵, JW Jack LEE⁶, Chun-Kwok WONG⁷, PW Alex LEE¹ and Lai-Shan Tam², ¹Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ³Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁴Bone Quality and Health Center of the Department of Orthopedics & Traumatology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁵Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong, ⁶Biostatistics Division, School of Public and Primary Care, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁷Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: PsA patients have higher cardiovascular disease risk due to underlying inflammation. While achieving MDA was associated with articular benefits, its effect on CVD risk…
Abstract Number: 1721 • 2016 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis Evolution during 5 Years of Anti-Tnfalpha Treatment in Psoriatic Arthritis Patients: Preliminary Data
Augusta Ortolan¹, Giovanni Boschetti², Mariagrazia Lorenzin¹, Giulia Cherobin³, Leonardo Punzi³, Massimo Puato² and Roberta Ramonda³, ¹Rheumatology Unit, Department of Medicine DIMED, Rheumatology Unit,University of Padova, Padova, Italy, ²Clinica Medica III, Department of Medicine DIMED, University of Padova, Padova, Italy, ³Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Background/Purpose: Psoriatic Arthritis (PsA) is associated with increased morbility and mortality and an accelerated atherosclerosis. Influence of anti-TNFalpha treatment (a widely used therapy in PsA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].